The USPTO issued B2 Patent US12590320B2 to Reflection Biotechnologies Limited, covering methods for treating ocular diseases including Bietti's Crystalline Dystrophy using gene therapy vectors that deliver CYP4V2 protein to retinal cells. The patent (CPC: C12N 15/86) was filed July 31, 2018, under Application No. 16635863, with 34 claims granted.

This is a routine patent grant notification establishing intellectual property protection. No compliance actions or deadlines apply. Pharmaceutical companies and healthcare providers developing gene therapies for inherited retinal diseases should note this patent when designing similar programs to avoid infringement. Legal and R&D teams should review the claims scope for potential licensing discussions.